摘要
Abstract
Objective To investigate the application value of tislelizumab plus chemotherapy in neoadjuvant therapy of operable esophageal cancer.Methods 70 patients with esophageal cancer in Luoyan Central Hospital Affiliated to Zhengzhou University from September 2021 to September 2024 were selected and divided into observation group and control group,with 35 cases in each group,randomly.All patients received surgical treatment.The control group was treated with neoadjuvant chemotherapy before the operation,while the observation group was treated with tislelizumab in combination on this basis.Clinical efficacy,tumor markers,immune function,quality of life and occurrence of adverse reactions were evaluated between the two groups.Results After treatment,objective response rate(ORR),disease control rate(DCR)in observation group were higher than those in control group(P<0.05);tumor markers CEA,CA199 and CA724 in the observation group were lower than those in the control group(P<0.05);the immune function indicators of the observation group were better than those of the control group(P<0.05);the scores of FACT-G in the observation group were higher than those in the control group(P<0.05).There was no statistical significance in the occurrence of adverse reaction between two groups(P>0.05).Conclusion The application of tislelizumab plus chemotherapy in the neoadjuvant therapy of operable esophageal cancer has significant effects with good quality and safety.which can improve the DCR and ORR of patients,reduce the level of tumor markers,improve the immune function of the body enhance the quality of life of patients with good safety.关键词
食管癌/新辅助化疗/替雷利珠单抗/临床疗效/安全性Key words
esophageal cancer/neoadjuvant chemotherapy/tislelizumab/clinical efficacy/safety分类
医药卫生
